Cost-Benefit Analysis of Sacubitril/Valsartan Among Patients with Heart Failure with Reduced Ejection Fraction in a Medicaid Population

Wednesday, April 22, 2020
Poster image
Alan Gabot, PharmD
Commonwealth Medicine
Pavel Lavitas, PharmD, BCPS
Commonwealth Medicine
Rachel Bacon, PharmD
Commonwealth Medicine
Thomas Pomfret, PharmD, MPH, BCPS
Commonwealth Medicine
Mckenzie Taylor, PharmD
Commonwealth Medicine
Karen Stevens, PharmD
Commonwealth Medicine
Tasmina Hydery, PharmD, MBA, CGP
Commonwealth Medicine
Andrew Coelho, PharmD.
Commonwealth Medicine
Bonnie Greenwood, PharmD, BCPS
Commonwealth Medicine
Caroline J. Alper, MD
Commonwealth Medicine
Karen Clements, ScD
Commonwealth Medicine
Pelin Fitzpatrick, MBA, MPSA
Commonwealth Medicine
Kimberly Lenz, PharmD
Commonwealth Medicine

This poster describes a study of a state Medicaid population, examining heart failure-related hospitalizations and emergency department(ED) visits to the treatment cost of managing heart failure pre- and post-sacubitril/valsartan initiation. Previous studies showed that patients who were treated with sacubitril/valsartan had lower rates of hospitalizations and costs. However, studies of the economic impact of sacubitril/valsartan for the Medicaid population is limited. This study concludes that the overall benefit (cost avoidance in hospitalizations/ED visits) did not outweigh the additional costs of sacubitril/valsartan. However, members that are more adherent to sacubitril/valsartan did have an overall benefit that outweighs the additional cost of sacubitril/valsartan.